Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Jun 11, 2025 | -$0.52 | -$0.62 | Miss |
| Mar 27, 2025 | -$0.91 | -$0.87 | Beat |
| Nov 14, 2024 | -$1.14 | -$1.03 | Beat |
| Sep 5, 2024 | -$1.00 | -$1.09 | Miss |
| Jun 12, 2024 | -$1.73 | -$1.38 | Beat |
| Mar 28, 2024 | -$1.59 | -$1.35 | Beat |